Discover科普上層樓羅氏藥廠的下個金雞母-瀰漫性大型B細胞淋巴瘤的第3線藥物Columvi (anti-CD20XCD3 bispecific Ab)
羅氏藥廠的下個金雞母-瀰漫性大型B細胞淋巴瘤的第3線藥物Columvi (anti-CD20XCD3 bispecific Ab)

羅氏藥廠的下個金雞母-瀰漫性大型B細胞淋巴瘤的第3線藥物Columvi (anti-CD20XCD3 bispecific Ab)

Update: 2023-10-24
Share

Description

難易度: *****
#Glofitamab#Columvi#Roche#羅氏藥廠#DLBCL#瀰漫性大型B細胞淋巴瘤#bispecificAb#雙特異性抗體#CD20XCD3#mosunetuzumab-axgb#epco’ritamab-bysp#ADC#CART#ORR#CompleteResponse#CytokineReleaseSyndrome
請我喝杯咖啡吧https://open.firstory.me/join/science-up
小額贊助支持本節目: https://open.firstory.me/user/ckn4fdez1q4vv0874tetbieq1
留言告訴我你對這一集的想法: https://open.firstory.me/user/ckn4fdez1q4vv0874tetbieq1/comments



Powered by Firstory Hosting
Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

羅氏藥廠的下個金雞母-瀰漫性大型B細胞淋巴瘤的第3線藥物Columvi (anti-CD20XCD3 bispecific Ab)

羅氏藥廠的下個金雞母-瀰漫性大型B細胞淋巴瘤的第3線藥物Columvi (anti-CD20XCD3 bispecific Ab)

科普上層樓